Onychomycosis Market Size Worth $ 5,689.46 Million By 2032 | CAGR: 4.6%

The global onychomycosis market size is expected to reach USD 5,689.46 million by 2032, according to a new study by Polaris Market Research. The report “Global Onychomycosis Market Size, Share, Trends, Industry Analysis Report: By Type, By Treatment (Topical, Oral and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) – Market Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The onychomycosis market is experiencing significant growth due to increased recognition of fungal diseases and improved public awareness. This has led to early detection and better understanding of the effects of fungal infections, such as onychomycosis.

In September 2023, the Centers for Disease Control and Prevention (CDC) recognized Fungal Disease Awareness Week (FDAW). Every year, the CDC and its partners participate in initiatives and outreach efforts to raise public awareness of fungal infections. Leading up to FDAW in 2023, various events emphasized the growing challenges, complexities, and significant impacts of fungal diseases.

Furthermore, lasers have received approval from the Food and Drug Administration (FDA), and technological advancements have led to the use of lasers in the treatment of onychomycosis, contributing to the expansion of the market.

As per the Indian Dermatology Online Journal, combining topical therapy with fractional CO2 laser can enhance the effectiveness of onychomycosis treatment. Several factors, such as nail plate thickness, extent and type of onychomycosis, number of sessions, and concurrent therapy, can influence treatment results. Fractional CO2 laser treatment involves creating openings in the nail, which improves the delivery of topical drugs by three to four times over 42 days. Therefore, using fractional CO2 laser as a pre-treatment alongside topical therapy for onychomycosis can be beneficial.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:https://www.polarismarketresearch.com/industry-analysis/onychomycosis-market/request-for-sample

Furthermore, oral treatment for onychomycosis is becoming increasingly popular among patients due to its higher success rates and shorter treatment durations compared to topical antifungals. The main treatment for this fungal infection is oral terbinafine hydrochloride. Many generic manufacturers are introducing oral treatments to address the growing prevalence of onychomycosis.

For instance, in June 2021, Glenmark Pharmaceuticals was granted approval by the U.S. FDA for their therapeutically equivalent and bioequivalent theophylline extended-release tablets, available in 450 mg and 300 mg for the treatment of onychomycosis.

Onychomycosis Market Report Highlights

• The distal subungual onychomycosis segment dominated the market. This is due to the rising number of approvals by the FDA in response to the increasing demand for more effective medications for onychomycosis treatment.
• The topical segment dominated the market over the forecast period as topical treatments are associated with fewer side effects.
• The North America region dominated the market over the forecast period owing to the increased occurrence of the target disease and supportive government policies.
• The Asia-Pacific region is expected to grow at the fastest CAGR owing to the limited access to healthcare services, poor hygiene practices, and extensive urbanization.
• The global key market players include Bausch Health Companies Inc., Moberg Pharma AB, Abbott, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., Novartis AG, Zydus Lifesciences and Sun Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the onychomycosis market report based on type, treatment, and region:

Onychomycosis, Type Outlook (Revenue - USD Million, 2019 - 2032)

• Distal Subungual Onychomycosis
• Proximal Subungual Onychomycosis
• White Superficial Onychomycosis
• Others

Onychomycosis, Treatment Outlook (Revenue - USD Million, 2019 - 2032)

• Topical
• Oral
• Others

Onychomycosis, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Australia
  • Malaysia
  • Vietnam
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Onychomycosis Report Scope: